Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Overview C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Companies Involved in Therapeutics Development AstraZeneca Plc ChemoCentryx Inc Dompe Farmaceutici SpA Eli Lilly and Co Merck & Co Inc Syntrix Biosystems Inc C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Drug Profiles AZD-5069 - Drug Profile Product Description Mechanism Of Action R&D Progress AZD-5069 + durvalumab - Drug Profile Product Description Mechanism Of Action R&D Progress DF-2755A - Drug Profile Product Description Mechanism Of Action R&D Progress Drug to Antagonize CXCR2 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress ladarixin - Drug Profile Product Description Mechanism Of Action R&D Progress LY-3041658 - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibodies to Antagonize CXCR2 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Antagonize CXCR2 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress navarixin - Drug Profile Product Description Mechanism Of Action R&D Progress PAC-G31P - Drug Profile Product Description Mechanism Of Action R&D Progress reparixin - Drug Profile Product Description Mechanism Of Action R&D Progress RIST-4721 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize CCR1 and CXCR2 for Solid and Hematological tumors - Drug Profile Product Description Mechanism Of Action R&D Progress SX-517 - Drug Profile Product Description Mechanism Of Action R&D Progress SX-576 - Drug Profile Product Description Mechanism Of Action R&D Progress SX-682 - Drug Profile Product Description Mechanism Of Action R&D Progress C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Dormant Products C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Discontinued Products C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Product Development Milestones Featured News & Press Releases Apr 08, 2019: Researchers report SX-682 could enhance multiple forms of T cell-based immunotherapies in solid tumors Mar 26, 2019: New study points to SX-682 as strategy to boost immunotherapy effectiveness in advanced colorectal cancer Feb 04, 2019: Syntrix wins $3.4M NIH grant to conduct phase 1/2 trial of SX-682 in Myelodysplastic Syndrome Apr 26, 2017: Trial investigates use of asthma drug for patients with heart conditions Dec 10, 2015: Research presented at the San Antonio Breast Cancer Symposium intended to strike at the heart of cancer stem cells Oct 05, 2015: Study Available at Fox Chase Cancer Center Evaluates the Use of Reparixin in Combination with Paclitaxel for the Treatment of Metastatic Triple Negative Breast Cancer Oct 01, 2014: Dompe commitment in oncology against cancer stem cells Sep 25, 2013: Pharmaceutical company Dompé launches REP0112, a trial to assess the efficacy and safety of Reparixin in autologous islet cell transplantation Jul 10, 2013: Dompé announces innovative treatment in the fight against type 1 diabetes: pancreatic islet cell transplantation, a hope that has already come true Dec 06, 2012: Dompé Announces Presentation Of Reparixin Clinical Trial Data In Metastatic Breast Cancer At 34th CTRC-AACR San Antonio Breast Cancer Symposium Oct 23, 2012: Dompé Announces Enrollment Of First Patient In Phase III Trial On Reparixin Oct 24, 2011: Dompé Announces Presentation Of Phase II Clinical Data Of Reparixin For Improvement Of Efficacy of Pancreatic Islet Transplantation At 2011 CTS-IXA Congress Oct 13, 2011: Dompé's Reparixin Receives EMA Orphan Drug Designation For Prevention Of Graft Rejection In Pancreatic Islet Transplantation Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2019 Number of Products under Development by Therapy Areas, H1 2019 Number of Products under Development by Indications, H1 2019 Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019 Number of Products under Development by Companies, H1 2019 Products under Development by Companies, H1 2019 Products under Development by Companies, H1 2019 (Contd..1), H1 2019 Number of Products under Investigation by Universities/Institutes, H1 2019 Products under Investigation by Universities/Institutes, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Stage and Route of Administration, H1 2019 Number of Products by Stage and Molecule Type, H1 2019 Pipeline by AstraZeneca Plc, H1 2019 Pipeline by ChemoCentryx Inc, H1 2019 Pipeline by Dompe Farmaceutici SpA, H1 2019 Pipeline by Eli Lilly and Co, H1 2019 Pipeline by Merck & Co Inc, H1 2019 Pipeline by Syntrix Biosystems Inc, H1 2019 Dormant Products, H1 2019 Dormant Products, H1 2019 (Contd..1), H1 2019 Discontinued Products, H1 2019List of Figures Number of Products under Development by Stage of Development, H1 2019 Number of Products under Development by Therapy Areas, H1 2019 Number of Products under Development by Top 10 Indications, H1 2019 Number of Products by Mechanism of Actions, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Top 10 Routes of Administration, H1 2019 Number of Products by Stage and Top 10 Routes of Administration, H1 2019 Number of Products by Top 10 Molecule Types, H1 2019 Number of Products by Stage and Top 10 Molecule Types, H1 2019

AstraZeneca Plc ChemoCentryx Inc Dompe Farmaceutici SpA Eli Lilly and Co Merck & Co Inc Syntrix Biosystems Inc